An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelson's syndrome, non-functioning adenoma, TSH-adenoma, Gonadotroph adenoma, and PRL-adenoma) with potential sensitivity to somatostatin analogues.
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2011
At a glance
- Drugs Pasireotide (Primary)
- Indications Adenoma; Nelson's syndrome; Neuroendocrine tumours; Pancreatic cancer; Pituitary adenoma
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 21 Jul 2011 New trial record